Clinical Trials Logo

Adverse Event clinical trials

View clinical trials related to Adverse Event.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06174844 Recruiting - Stress Clinical Trials

Assessment of the Humanisation of Care in Hospitals in Andalusia-Spain

HUMANCUIDA
Start date: January 1, 2024
Phase:
Study type: Observational

Observational assessment through patient interviews of relational, structural and organisational aspects related to the humanisation of health care. These data will be related to health outcomes such as pain, sleep quality, anxiety levels, adverse events (pressure injuries, falls, and mortality), satisfaction with the care received, and experience in communication processes with health professionals. Data will also be collected on work ergonomics variables (stress, burnout, working conditions, ratios) of nurses and health technicians, which will also be related to the health outcomes collected.

NCT ID: NCT05862103 Recruiting - Clinical trials for Acute Myocardial Infarction

Long-Term Follow-Up in Patients With Acute Myocardial Infarction Cohort

Start date: December 20, 2022
Phase:
Study type: Observational

AMI Survivors who participated in the project "Construction and key technology research of the whole myocardial protection system for acute myocardial infarction" (project number 2016YFC1301100) and completed the 1-year visit were followed up by telephone at 3 years (within the corresponding follow-up time window) and 5 years after discharge to acquire the patients' medication, health status, and major adverse cardiovascular and cerebrovascular events, including death, heart failure, rehospitalization, re-myocardial infarction, revascularization, stroke, malignant arrhythmia, and bleeding events.

NCT ID: NCT05818826 Recruiting - Septic Shock Clinical Trials

Early Versus Conventional Cessation of Hydrocortisone in Septic Shock

CESSHYDRO
Start date: July 5, 2023
Phase: Phase 2
Study type: Interventional

Septic shock is one of the causes of death in ICU and hospital. Refractory shock is the problem which healthcare providers should recognize though it is difficult to handle with. The corticosteroid called hydrocortisone is one of the treatment in refractory septic shock which requires vasopressor to maintain blood pressure. In recovery phase of septic shock and weaning off vasopressor, there is no definite way to taper off hydrocortisone.

NCT ID: NCT05462938 Recruiting - Clinical trials for Postoperative Delirium

Conscious Sedation for Transcatheter Aortic Valve Implantation

Start date: November 11, 2021
Phase: N/A
Study type: Interventional

Aortic valve stenosis is the heart valve disease with the highest prevalence among the elderly, and may lead to heart failure. Until recently, the only definitive treatment was surgical replacement (SAVR). However, the increased risk associated with the surgical procedure excluded patients with multiple co-morbidities. As the population is aging and more and more patients may present with aortic stenosis, the need of a less invasive approach has emerged. Transcatheter Aortic Valve Replacement (TAVR) offered an alternative therapy for these high risk patients. This new method has seen worldwide acceptance, has been proven very beneficial for these patients, and therefore its indications have been expanded to intermediate risk patients, as well. Until recently, general anesthesia was the primary anesthetic technique for TAVR, but conscious sedation or monitored anesthesia care (MAC) is gaining more and more popularity lately. Our knowledge regarding the comparison between general anesthesia and MAC in TAVR procedures is derived mainly from observational studies and few randomized trials. MAC seems to be associated with less inotropic drug usage, shorter procedural times, shorter intensive care unit (ICU) and hospital length of stay. However, according to published data, there were no differences in 30-day mortality and complications between these two techniques. Even less are known about the most suitable anesthetic agent for MAC during TAVR. Many drugs have been used, with propofol and dexmedetomidine being the most popular. However, there are only few comparative studies and their results are not conclusive. This study compares MAC under propofol and MAC under dexmedetomidine for TAVR in order to examine which method of conscious sedation comes with more beneficial postoperative outcomes for the patients.

NCT ID: NCT05369962 Recruiting - Frailty Clinical Trials

Adverse Event Prediction in Geriatric Patients in the ED With Ultrasound

AGEDU
Start date: May 10, 2022
Phase:
Study type: Observational [Patient Registry]

The aim of this study is to evaluate whether ultrasound measurements of the Qcsa can be utilized to identify older patients who are at risk for functional decline, ED revisit or death.

NCT ID: NCT05282654 Recruiting - Adverse Event Clinical Trials

Real-time Symptom Monitoring Using ePROs to Prevent Adverse Events During Care Transitions

Start date: February 1, 2022
Phase: N/A
Study type: Interventional

This study aims to predict and minimize post-discharge adverse events (AEs) during care transitions through early identification and escalation of patient-reported symptoms to inpatient and ambulatory clinicians by way of predictive algorithms and clinically integrated digital health apps. We will (1) develop and prospectively validate a predictive model of post-discharge AEs for patients with multiple chronic conditions (MCC); (2) combine, adapt, extend, and iteratively refine our EHR-integrated digital health infrastructure in a series of design sessions with patient and clinician participants; (3) conduct a RCT to evaluate the impact of ePRO monitoring on post-discharge AEs for MCC patients discharged from the general medicine service across Brigham Health; and (4) use mixed methods to evaluate barriers and facilitators of implementation and use as we develop a plan for sustainability, scale, and dissemination.

NCT ID: NCT03740464 Recruiting - Clinical trials for Epithelial Ovarian Cancer

Long-acting G-CSF for Febrile Neutropenia

Start date: November 10, 2018
Phase: Phase 3
Study type: Interventional

This study aims to analyze the effects of long-acting granulocyte colony stimulating factor (G-CSF) on the prevention febrile neutropenia (FN) in epithelial ovarian cancer. Patients are randomized into study group and control group. In study group, patients accept long-acting G-CSF 48 hours from the chemotherapy. While the control group accept regular treatment rather than long-acting G-CSF. The primary end is the incidence of FN in every course of chemotherapy. The secondary ends include: the incidences of myelosuppression, doses of G-CSF and its expenses, visits to outpatient and emergency clinics, adverse events related to G-CSF.

NCT ID: NCT03668639 Recruiting - Cervical Cancer Clinical Trials

Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin

Start date: September 5, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

This is a multicentre, single-arm, phase II study to investigate the safety and antiemetic efficacy of Akynzeo (a fixed dose combination of palonosetron and netupitant) plus dexamethasone in patients receiving concomitant chemo-radiotherapy with weekly cisplatin for at least five weeks.

NCT ID: NCT03436381 Recruiting - Sleep Apnea Clinical Trials

Can Sleep Apnea Screening Questionnaire Predict Adverse Events in Endoscopic Studies

Start date: February 9, 2018
Phase:
Study type: Observational [Patient Registry]

Investigators hypothesize that the obese population (BMI ≥30 kg/m2) who might be at higher risk for obstructive sleep apnea (OSA), carries a higher risk of endoscopy associated adverse events. The primary aim of our study is to determine predictors of endoscopy associated adverse events (airway maneuvers and sedation related complications) in the obese population including the use of the STOP-BANG questionnaire (SBQ) and Epworth Sleepiness Scale (ESS). A secondary aim is to determine the impact of referral to sleep medicine clinic and home sleep test ordered from the gastroenterologist if patient was found to be high risk for OSA by the use of validated questionnaires such as SBQ and ESS.

NCT ID: NCT03381534 Recruiting - Adverse Event Clinical Trials

Safety and Efficacy of Distal Embolic Protection Device in Vertebral Artery Origin Stenting

Start date: May 20, 2017
Phase: N/A
Study type: Interventional

This is a prospective single-center,randomized controlled trial,aiming to investigate the safety and efficacy of distal EPD in vertebral artery origin stenting(VAOS);256 subjects will be recruited in this study,after randomized recruitment, treatment group(128 subjects each group) undergo VAOS with adjuvant distal embolic protection device(EPD),control group undergo routine VAOS without distal embolic protection device.Intraprocedural and postprocedural in-hospital adverse events,including stroke,death and dis-retrieval of EPD,will be noted and cost-effectiveness analysis also will be conduct,including economic cost,hospital stays.